Almoosa Health Co. announces its Interim Financial results for the Period Ending on 2026-03-31 ( Three Months )

Element List	Current Quarter	Similar quarter for previous year	%Change	Previous Quarter	% Change
Sales/Revenue	348.3	323	7.832	388	-10.231
Gross Profit (Loss)	97	98.8	-1.821	120.3	-19.368
Operational Profit (Loss)	40.1	51.6	-22.286	62.3	-35.634
Net Profit (Loss) Attributable to Shareholders of the Issuer	23.5	67.2	-65.029	52.2	-54.98
Total Comprehensive Income Attributable to Shareholders of the Issuer	25.1	67.3	-62.704	56.3	-55.417
All figures are in (Millions) Saudi Arabia, Riyals

Element List	Current Period	Similar period for previous year	%Change
Total Shareholders Equity (after Deducting Minority Equity)	1,933.8	1,835	5.384
Profit (Loss) per Share	0.53	1.54
All figures are in (Millions) Saudi Arabia, Riyals

Element List	Amount	Percentage of the capital (%)
Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value	-	-
All figures are in (Millions) Saudi Arabia, Riyals

Element List	Explanation
The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the same quarter of the last year is	The Company achieved revenue growth of 7.8% during the current quarter compared to the corresponding quarter of the previous year, driven by the continued expansion of its healthcare services and enhanced operational capacity across its facilities. Notably, the Rehabilitation Hospital delivered strong performance, recording a year-on-year growth of 48.3%, contributing positively to overall revenues.

Element List

Explanation

The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the same quarter of the last year is

The Company achieved revenue growth of 7.8% during the current quarter compared to the corresponding quarter of the previous year, driven by the continued expansion of its healthcare services and enhanced operational capacity across its facilities. Notably, the Rehabilitation Hospital delivered strong performance, recording a year-on-year growth of 48.3%, contributing positively to overall revenues.

The Company expects this growth momentum to continue in the coming quarters, supported by ongoing expansions of existing hospitals and medical centres, as well as the opening of new medical centres.

It is worth noting that the first quarter of 2026 was a softer period, as it included the holy month of Ramadan and the Eid Al-Fitr holiday, which generally result in lower patient volumes and reduced elective procedures, as inpatient patients tend to defer elective surgeries to the post-holiday period.

In addition, the quarter was impacted by regional geopolitical developments, which contributed to a softer operating environmentThe reason of the increase (decrease) in the net profit during the current quarter compared to the same quarter of the last year is The Company’s net profit for Q1-26 amounted to SAR 23.5 million compared to SAR 67.2 million in Q1-25, a decrease of 65.0%. One of the key reasons driven by a swing in derivative financial instruments, which moved from a gain of SAR 16.1 million in Q1-25 to a loss of SAR 13.3 million in Q1-26.

This was further impacted by the normalization of finance income following the deployment of IPO proceeds, as well as an increase in general and administrative expenses, reflecting continued investment in the Company’s operational infrastructure and the ramp-up of recently opened medical centres.

Despite revenue growth of 7.8%, reaching SAR 348.3 million, gross and operating margins came under pressure during the quarter, resulting in a decline in net profit. This was primarily attributable to the initial ramp-up phase and associated operating costs of two newly opened large medical centres, while the quarter also remained seasonally softer in nature.

Additionally, the prior period included a zakat credit that did not recur in the current period.

Excluding the impact of derivative financial instruments, the Company’s core business fundamentals remain strong, and management remains focused on sustaining its growth trajectory and enhancing operational efficiencies in the coming quarters.The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the previous one is The decrease in net Sales during Q1-26 compared to Q4-25 is primarily attributable to lower revenues, which declined by 10.2% to SAR 348.3 million from SAR 388.0 million in the preceding quarter. This reduction is largely cyclical in nature, as Q1-26 encompassed the holy month of Ramadan and the Eid Al-Fitr holiday, periods which typically witness lower patient volumes and reduced elective procedure activity across the healthcare sector.

This seasonal pattern is consistent with prior years and does not reflect any underlying change in the Company’s operational performance or business strategyThe reason of the increase (decrease) in the net profit (loss) during the current quarter compared to the previous one is The Company’s net profit for Q1-26 amounted to SAR 23.5 million compared to SAR 52.2 million in Q4-25, a decrease of 55%. The decline was primarily seasonal in nature, as Q1-26 included the holy month of Ramadan and the Eid Al-Fitr holiday, which typically result in lower patient volumes and reduced elective procedure activity, leading to a 10.2% decline in revenues to SAR 348.3 million.

The decrease in revenues, combined with a relatively higher cost base, resulted in a compression in gross margin from 31.0% in Q4-25 to 27.9% in Q1-26.

Further contributing to the decline was a reduction in Gain / (loss) on investments, which normalized from an elevated level, alongside an improvement in investment-related results, with a gain of SAR 0.8 million recorded in Q1-26 compared to a loss of SAR 4.6 million in Q4-25, partially offsetting the overall decline.

In Q1 2026, finance costs also decreased by 51.3%, providing further support to the bottom line.

In addition, the quarter was modestly impacted by regional geopolitical developments, which had a limited effect on overall activity levels.

The Company’s underlying business fundamentals remain intact, with management focused on planned growth through the expansion of existing projects, enhancing operational efficiencies, strengthening synergies across services, and rationalizing costs.Statement of the type of external auditor's report Unmodified conclusionComment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion) N/AReclassification of Comparison Items N/AAdditional Information It should be noted that statutory net income was impacted by a non-cash Mark-to-Market loss on derivative financial instruments. The derivative financial instruments recorded a loss of SAR 13.3 million in Q1-26 compared to a gain of SAR 16.1 million in Q1-25, resulting in a combined swing of SAR 29.4 million, which materially impacted the year-on-year comparison of reported net profit.

To provide a clearer view of the Company’s underlying operational performance, the adjusted net profit, excluding the impact of gain/(loss) on derivative financial instruments, amounted to SAR 36.8 million in Q1-26 compared to SAR 51.1 million in Q1-25, a decline of 28.0%, which is significantly moderate than the reported decline of 65.0%.

Excluding this non-cash item, the adjusted net profit margin stood at 10.6% in Q1-26 versus 15.8% in Q1-25, reflecting the Company’s continued stable operational performance, supported by revenue growth of 7.8%, despite the impact of overhead costs associated with the ramp-up phase of two newly opened large medical centres

The Board of Directors approved a cash dividend of SAR 0.25 per share, amounting to SAR 11.1 million, for the First quarter of 2026.

Almoosa Health intends to hold an Earnings Call, Thursday, 14 May 2026, at 3:00 PM (Saudi Time) to address questions from investors and analysts regarding the financial results for Q1 2026. Investors can register via the attached invitation.Attached Documents

The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.